Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Neoplasms 8 cyclopia sequence 7 Prostatic Neoplasms 7 Polycystic Ovary Syndrome 5 Fatigue 5 Lung Neoplasms 4 Head and Neck Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Pain 3 Obesity 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Leiomyoma 3 Vomiting 2 Urinary Bladder Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Neoplasms, Plasma Cell 2 Nausea 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Insulin Resistance 2 Infertility 2 Hyperandrogenism 2 Hematologic Diseases 2 Depression 2 Burkitt Lymphoma 2 Weight Loss 1

Interventions

Doxorubicin 25 Radiotherapy 15 Ifosfamide 14 Trabectedin 10 pazopanib 6 ribociclib 5 pembrolizumab 5 Specimen Handling 5 Gemcitabine 5 Biopsy 5 palbociclib 4 Magnetic Resonance Spectroscopy 4 Docetaxel 4 Chemotherapy, Adjuvant 4 selinexor 3 liposomal doxorubicin 3 eribulin 3 X-Rays 3 Vincristine 3 Radiation 3 Neoadjuvant Therapy 3 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 toripalimab 2 temsirolimus 2 romidepsin 2 pegfilgrastim 2 cixutumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Liposarcoma × Sugars × Clear all

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡